Clemence Ginet

Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

TERT drives liver tumorigenesis beyond telomere elongation.

TERT drives liver tumorigenesis beyond telomere elongation.

Journal: Life science alliance

Published: February 10, 2026

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Journal: International journal of molecular sciences

Published: October 23, 2019

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

Journal: Oncotarget

Published: November 22, 2016

DNA Damage and the Activation of the p53 Pathway Mediate Alterations in Metabolic and Secretory Functions of Adipocytes.

DNA Damage and the Activation of the p53 Pathway Mediate Alterations in Metabolic and Secretory Functions of Adipocytes.

Journal: Diabetes

Published: January 04, 2016

Inhibition of Noninfectious Uveitis Using Intravenous Administration of Collagen II-Specific Type 1 Regulatory T Cells.

Inhibition of Noninfectious Uveitis Using Intravenous Administration of Collagen II-Specific Type 1 Regulatory T Cells.

Journal: Investigative ophthalmology & visual science

Published: October 09, 2015

Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.

Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death.

Journal: Oncotarget

Published: September 29, 2015

Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.

Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib.

Journal: Oncoscience

Published: October 10, 2014

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Journal: Oncotarget

Published: March 23, 2013

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.

Journal: Haematologica

Published: January 10, 2013

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Journal: Oncotarget

Published: December 15, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026